Global Durvalumab Market Overview:
Global Durvalumab Market is expected to grow at a significant rate during the forecast period 2026-2035, with 2025 as the base year.
Global Durvalumab Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Durvalumab involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Durvalumab Market:
The Durvalumab Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Durvalumab Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Durvalumab Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Durvalumab market has been segmented into:
2.4mL Injection
10mL Injection
By Application, Durvalumab market has been segmented into:
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Durvalumab market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Durvalumab market.
Top Key Players Covered in Durvalumab market are:
AstraZeneca
Bristol-Myers Squibb
Merck & Co.
Inc.
Pfizer
Inc.
F. Hoffmann-La Roche AG
Eli Lilly and Company
Sanofi
AbbVie
Inc.
Regeneron Pharmaceuticals
Inc.
Novartis International AG.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Durvalumab Market by Type
4.1 Durvalumab Market Snapshot and Growth Engine
4.2 Durvalumab Market Overview
4.3 2.4mL Injection
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 2.4mL Injection: Geographic Segmentation Analysis
4.4 10mL Injection
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 10mL Injection: Geographic Segmentation Analysis
Chapter 5: Durvalumab Market by Application
5.1 Durvalumab Market Snapshot and Growth Engine
5.2 Durvalumab Market Overview
5.3 Locally Advanced Urothelial Carcinoma
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Locally Advanced Urothelial Carcinoma: Geographic Segmentation Analysis
5.4 Metastatic Urothelial Carcinoma
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Metastatic Urothelial Carcinoma: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Durvalumab Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ASTRAZENECA
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 BRISTOL-MYERS SQUIBB
6.4 MERCK & CO.
6.5 INC.
6.6 PFIZER
6.7 INC.
6.8 F. HOFFMANN-LA ROCHE AG
6.9 ELI LILLY AND COMPANY
6.10 SANOFI
6.11 ABBVIE
6.12 INC.
6.13 REGENERON PHARMACEUTICALS
6.14 INC.
6.15 AND NOVARTIS INTERNATIONAL AG.
Chapter 7: Global Durvalumab Market By Region
7.1 Overview
7.2. North America Durvalumab Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 2.4mL Injection
7.2.4.2 10mL Injection
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Locally Advanced Urothelial Carcinoma
7.2.5.2 Metastatic Urothelial Carcinoma
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Durvalumab Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 2.4mL Injection
7.3.4.2 10mL Injection
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Locally Advanced Urothelial Carcinoma
7.3.5.2 Metastatic Urothelial Carcinoma
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Durvalumab Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 2.4mL Injection
7.4.4.2 10mL Injection
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Locally Advanced Urothelial Carcinoma
7.4.5.2 Metastatic Urothelial Carcinoma
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Durvalumab Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 2.4mL Injection
7.5.4.2 10mL Injection
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Locally Advanced Urothelial Carcinoma
7.5.5.2 Metastatic Urothelial Carcinoma
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Durvalumab Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 2.4mL Injection
7.6.4.2 10mL Injection
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Locally Advanced Urothelial Carcinoma
7.6.5.2 Metastatic Urothelial Carcinoma
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Durvalumab Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 2.4mL Injection
7.7.4.2 10mL Injection
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Locally Advanced Urothelial Carcinoma
7.7.5.2 Metastatic Urothelial Carcinoma
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Durvalumab Scope:
|
Report Data
|
Durvalumab Market
|
|
Durvalumab Market Size in 2025
|
USD XX million
|
|
Durvalumab CAGR 2025 - 2032
|
XX%
|
|
Durvalumab Base Year
|
2024
|
|
Durvalumab Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
AstraZeneca, Bristol-Myers Squibb, Merck & Co., Inc., Pfizer, Inc., F. Hoffmann-La Roche AG, Eli Lilly and Company, Sanofi, AbbVie, Inc., Regeneron Pharmaceuticals, Inc., and Novartis International AG..
|
|
Key Segments
|
By Type
2.4mL Injection
10mL Injection
By Applications
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
|
